Avaliação do tratamento da psoríase com esomeprazol - estudo piloto

Bafutto, Mauro; Oliveira, Enio Chaves; Zaterka, Schlioma.
Arq. gastroenterol ; 56(3): 261-263, July-Sept. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1038723

Documentos relacionados

  1. EVALUATION OF PSORIASIS TREATMENT WITH ESOMEPRAZOLE - A PILOT STUDY.
  2. [Esomeprazol-induced cutaneous lupus erythematosus].
  3. An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding.
  4. Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease.
  5. Esomeprazole inhibits endoplasmic reticulum stress and ameliorates myocardial ischemia-reperfusion injury.
  6. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan.
  7. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
  8. Effectiveness of Rabeprazole and Other Proton Pump Inhibitors in Managing GERD with Varying Severity: A Retrospective, Real-world EMR-based Study (POWER GERD Study).
  9. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
  10. Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.